1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

Complexity of manufacturing Teva's COPAXONE®

Teva's process of quality and consistency1,2

Teva’s Shared Solutions® offers a full range of support services to help your COPAXONE® patients reach their treatment goals
See All Services
COPAXONE® has a history steeped in scientific exploration and dedication to relapsing MS care
SEE STUDY RESULTS

References

  1. COPAXONE® (glatiramer acetate injection) prescribing information. Rev. 8/2016. Teva Neuroscience, Inc.
  2. Citizen Petition Requesting That FDA Refrain From Approving Any Abbreviated New Drug Application Referencing Copaxone® Until Certain Conditions Are Met. December 5, 2013. Teva Neuroscience, Inc.
  3. Schellekens H, Klinger E, Muhlebach S, et al. Regul Toxicol Pharmacol. 2011;59(1):176-183.
  4. Johnson KP. Expert Opin Drug Metab Toxicol. 2010;6(5):643-660.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site
×